The U.S. Court has vacated the Modified Consent Decree imposed on Xellia Pharmaceuticals’ Cleveland, Ohio facility in 2016.
Xellia to axe 80 positions at the plant it bought from BI
Xellia starts commercial production and distribution of premix bag products
Xellia's Generic Cyclophosphamide Receives Approval in the U.S.
Enforcement Report - Week of September 1, 2021
COPENHAGEN, Denmark & BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
Xellia Pharms Aps's Generic Micafungin Sodium Receives ApprovalIn US
Xellia Pharmaceuticals, a manufacturer of specialty anti-infective treatments, has become a member of Medicines for Europe.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.
Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, has received approval for 3 additional dosages of VANCO READYTM, expanding its range of room-temperature-stable, ready-to-use (RTU) Vancomycin injection premix bags.